Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Pharmacodynamic Models: Linear Concentration–Effect Model01:15

Pharmacodynamic Models: Linear Concentration–Effect Model

The linear concentration–effect model, underpinned by the principle that pharmacological effect (E) is directly proportional to plasma drug concentration (C), emerges as a pivotal simplification of the Emax model for conditions where C is significantly less than EC50. This model portrays a linear trajectory of the concentration–effect relationship when drug levels are markedly below the EC50 threshold.Despite its inherent assumption of continuous effect augmentation with increasing drug...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sensitivity of HiFi long-read genome sequencing for difficult-to-detect pathogenic variants when applied to real-world clinical laboratory samples.

American journal of human genetics·2026
Same author

Structural Evaluation of <i>RYR2</i>-CPVT Missense Variants and Continuous Bayesian Estimates of Their Penetrance.

Circulation. Genomic and precision medicine·2026
Same author

Return of genome-informed risk-assessment results for common conditions to 23,840 adults and children: An eMERGE network study.

American journal of human genetics·2026
Same author

The Electronic Medical Records and Genomics study: Design and analytic framework for assessing the impact of genome-informed risk assessments.

American journal of human genetics·2026
Same author

Diagnostic genetic testing indications and findings in type II, IX and XI collagenopathies.

Journal of medical genetics·2026
Same author

Diagnostic yield of exome reanalysis over time: Contribution of reevaluation type, timing, and patient phenotype.

Genetics in medicine : official journal of the American College of Medical Genetics·2026

Related Experiment Video

Updated: May 12, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.6K

Calibrated Functional Data Decreases Clinical Uncertainty for KCNH2-related Long QT Syndrome.

Chai-Ann Ng1,2, Matthew J O'Neill3, Samskruthi R Padigepati4

  • 1Mark Cowley Lidwill Research Program in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia.

Medrxiv : the Preprint Server for Health Sciences
|February 20, 2025
PubMed
Summary

Rare missense variants are often classified as variants of uncertain significance (VUS), leading to patient anxiety and unnecessary medical tests. High-throughput experimental data can help reduce VUS, but optimal strategies require further study.

More Related Videos

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

10.9K
Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.1K

Related Experiment Videos

Last Updated: May 12, 2026

In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

20.6K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

10.9K
Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

1.1K

Area of Science:

  • Genetics
  • Genomic Medicine
  • Clinical Diagnostics

Background:

  • Rare missense variants are frequently classified as variants of uncertain significance (VUS) due to limited evidence.
  • This classification ambiguity causes patient distress and can lead to extensive, often unnecessary, medical evaluations, known as the 'diagnostic odyssey'.

Purpose of the Study:

  • To assess the potential of high-throughput experimental data in reducing the number of VUS identified in clinical genetic testing.
  • To explore optimal strategies for leveraging experimental data to improve variant classification accuracy.

Main Methods:

  • Review of existing literature on high-throughput experimental data for variant classification.
  • Analysis of case studies demonstrating the impact of experimental data on VUS reduction.
  • Discussion of methodologies for integrating experimental data into clinical genetic testing workflows.

Main Results:

  • High-throughput experimental data show significant promise in reclassifying VUS.
  • The extent of VUS reduction varies depending on the type of experimental data and variant.
  • Further research is needed to establish standardized protocols for data generation and interpretation.

Conclusions:

  • Well-validated high-throughput experimental data can substantially decrease the VUS classification rate.
  • Optimal strategies for utilizing this data in clinical settings are still under development.
  • Reducing VUS is crucial for improving diagnostic accuracy and patient care in genetic testing.